The aim of this study was to compare skin autofluorescence caused by advanced glycation end-products (AGEs) with biochemical markers of endothelial dysfunction and soluble receptor for AGEs (sRAGE) in patients with diabetes. Skin autofluorescence (AF) assessed by AGE-Reader was evaluated with sRAGE and other biochemical parameters in 88 patients with diabetes (47 Type 1/T1DM/ and 41 Type 2/T2DM/) and 20 controls. Skin AF was significantly higher in T1DM and T2DM in comparison to controls (2.39 ± 0.54, 2.63 ± 0.73 versus 1.96 ± 0.33 AU; P < 0.0001). Positive correlation of AF with sRAGE was detected in T1DM and T2DM (r = 0.37, P < 0.02 and r = 0.60, P < 0.0001), but not in controls. Significantly higher AF values were found in patients with positive albuminuria as compared to those with normal albuminuria. Similarly, higher AF was detected in patients with endothelial dysfunction expressed by vWF, ICAM-1, and VCAM-1. Multiple regression analysis revealed independent association of skin AF with age, sRAGE, and albumin-creatinine ratio in patients with diabetes (R (2) = 0.38). Our study confirms that AF is elevated in patients with diabetes, especially with positive albuminuria and endothelial dysfunction. The strong and independent relationship between AF and sRAGE supports the idea that AF may reflect AGEs/RAGE interactions. The exact mechanism remains to be established.

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague General University Hospital Prague 128 08 Prague 2 Czech Republic ; 3rd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague General University Hospital Prague 128 08 Prague 2 Czech Republic

Zobrazit více v PubMed

Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54(11):3103–3111. PubMed PMC

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. PubMed

Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. Journal of Hypertension. 2007;25(3):577–583. PubMed

Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. Journal of Clinical Investigation. 1994;94(1):110–117. PubMed PMC

Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889–901. PubMed

Haslbeck KM, Schleicher E, Bierhaus A, et al. The AGE/RACE/NF-κB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT) Experimental and Clinical Endocrinology and Diabetes. 2005;113(5):288–291. PubMed

Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010;59(1):249–255. PubMed PMC

Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009;52(11):2251–2263. PubMed

Yan SF, Yan SD, Ramasamy R, Schmidt AM. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Annals of Medicine. 2009;41(6):408–422. PubMed PMC

Katakami N, Matsuhisa M, Kaneto H, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes and Vascular Disease Research. 2008;5(3):190–197. PubMed

Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical Pharmacology. 2010;79(10):1379–1386. PubMed PMC

Vazzana N, Santilli F, Cuccurullo C, Davì G. Soluble forms of RAGE in internal medicine. Internal and Emergency Medicine. 2009;4(5):389–401. PubMed

Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA(1c) as markers of diabetic complications. Diabetes. 1999;48(4):870–880. PubMed PMC

Chiarelli F, De Martino M, Mezzetti A, et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. Journal of Pediatrics. 1999;134(4):486–491. PubMed

Meerwaldt R, Lutgers HL, Links TP, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care. 2007;30(1):107–112. PubMed

Münch G, Keis R, Weßels A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA1. European Journal of Clinical Chemistry and Clinical Biochemistry. 1997;35(9):669–677. PubMed

Meerwaldt R, Graaf R, Oomen PHN, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47(7):1324–1330. PubMed

Sattar N. Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabetic Medicine. 2012;29:5–13. PubMed

Monami M, Lamanna C, Gori F, Bartalucci F, Marchionni N, Mannucci E. Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Research and Clinical Practice. 2008;79(1):56–60. PubMed

Mulder DJ, Van De Water T, Lutgers HL, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation end-products: an overview of current clinical studies, evidence, and limitations. Diabetes Technology and Therapeutics. 2006;8(5):523–535. PubMed

Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical Journal. 2003;370(3):1097–1109. PubMed PMC

Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease: data From the Bezafibrate Infarction Prevention (BIP) Study. Journal of the American College of Cardiology. 2002;39(7):1133–1138. PubMed

Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology. 2003;42(7):1149–1160. PubMed

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine. 1999;130(6):461–470. PubMed

Nienhuis HL, De leeuw K, Bijzet J, et al. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation end-products. Rheumatology. 2008;47(10):1554–1558. PubMed

Mulder DJ, van Haelst PL, Gross S, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis. 2008;197(1):217–223. PubMed

Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovascular Diabetology. 2007;6, article 9 PubMed PMC

Kalousová M, Jáchymová M, Oto M, et al. Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrology Dialysis Transplantation. 2007;22(7):2020–2026. PubMed

Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31(3):517–521. PubMed

Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit AJ, Gans RO. Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9) Journal of Diabetes Science and Technology. 2008;2:572–577. PubMed PMC

Furth AJ. Glycated proteins in diabetes. British Journal of Biomedical Science. 1997;54(3):192–200. PubMed

de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CGM, Bijl M. Advanced glycation end-products are increased in rheumatoid arthritis patients with controlled disease. Arthritis Research & Therapy. 2011;13, article R205 PubMed PMC

Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S. Soluble receptor for advanced glycation end products in patients with decreased renal function. American Journal of Kidney Diseases. 2006;47:406–411. PubMed

Kankova K, Kalousova M, Hertlova M, Krusova D, Olsovsky J, Zima T. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Archives of Physiology and Biochemistry. 2008;114:111–119. PubMed

Lutgers HL, Gerrits EG, Graaff R, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52(5):789–797. PubMed